NeuBase Therapeutics, Inc. Skyrocketed

Thu, Nov 30, 2023 at 07:42 PM

NeuBase Therapeutics, Inc. (NBSE:NASDAQ) soared at $0.99, representing a gain of 53.4%. On Thu, Nov 30, 2023, NBSE:NASDAQ touched a New 2-Week High of $0.99. From Thu, Nov 16, 2023, the stock recorded 55.56% Up Days and 40.00% Green Days

The stock spiked on Thu, Nov 30, 2023 at $1.51 with a volume of 14M+.

About NeuBase Therapeutics, Inc. (NBSE:NASDAQ)

Ohr Pharmaceutical Inc is a US-based pharmaceutical company which focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. The lead product of the company is topical Squalamine is a novel therapeutic product which provides non-invasive therapy to improve visual outcomes. Its product pipeline includes SQUALAMINE LACTATE OPHTHALMIC SOLUTION 0.2%, SKS sustained release ocular drug delivery platform technology, Animal Model for Dry-AMD, and Non-Ophthalmology Assets.

Top 10 Gainers:

Ampio Pharmaceuticals, Inc. (AMPE:NYSEMKT), 193.89%
Signature Bank (SBNY:NASDAQ), 150%
Soligenix, Inc. (SNGX:NASDAQ), 135.97%
Incannex Healthcare Limited (IXHL:NASDAQ), 84.95%
ImmunoGen, Inc. (IMGN:NASDAQ), 82.75%
SeaChange International, Inc. (SEAC:NASDAQ), 74.22%
Intelligent Bio Solutions Inc Com (INBS:NASDAQ), 61.35%
Smart for Life Inc. (SMFL:NASDAQ), 58.55%
NeuBase Therapeutics, Inc. (NBSE:NASDAQ), 53.38%
Etao International Co. Ltd. (ETAO:NASDAQ), 50.6%